Sensei Biotherapeutics (NASDAQ:SNSE) Posts Earnings Results, Misses Estimates By $130.83 EPS

Sensei Biotherapeutics (NASDAQ:SNSE) announced its quarterly earnings results on Friday. The company reported ($131.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83), FiscalAI reports.

Sensei Biotherapeutics Trading Up 3.1%

Shares of SNSE stock traded up $0.61 on Friday, hitting $20.43. 40,624 shares of the stock were exchanged, compared to its average volume of 30,397. The firm has a market capitalization of $27.38 million, a P/E ratio of -1.23 and a beta of -0.18. The business has a 50-day moving average of $28.89 and a 200 day moving average of $17.87. Sensei Biotherapeutics has a fifty-two week low of $5.25 and a fifty-two week high of $36.76.

Insider Buying and Selling at Sensei Biotherapeutics

In other news, major shareholder Millennium Management Llc acquired 15,321 shares of Sensei Biotherapeutics stock in a transaction dated Friday, March 27th. The stock was bought at an average cost of $26.61 per share, with a total value of $407,691.81. Following the completion of the transaction, the insider directly owned 142,360 shares of the company’s stock, valued at approximately $3,788,199.60. This represents a 12.06% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders bought 46,980 shares of company stock worth $1,341,669 and sold 23,067 shares worth $704,439. 23.20% of the stock is owned by corporate insiders.

Institutional Trading of Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC lifted its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,516 shares of the company’s stock after purchasing an additional 1,100 shares during the quarter. Renaissance Technologies LLC owned 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent SEC filing. 10.50% of the stock is currently owned by hedge funds and other institutional investors.

More Sensei Biotherapeutics News

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Friday, April 24th. Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a research report on Tuesday, April 21st. Finally, Leerink Partners initiated coverage on shares of Sensei Biotherapeutics in a research report on Monday, April 20th. They set an “outperform” rating and a $50.00 price objective for the company. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $40.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.